

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
28 February 2002 (28.02.2002)

PCT

(10) International Publication Number
WO 02/15886 A2

- (51) International Patent Classification⁷: **A61K 9/20**, (74) Agents: **FORBES, James, C. et al.**; Pharmacia Corporation, P.O. Box 5110, Chicago, IL 60680 (US).
31/635
- (21) International Application Number: PCT/US01/25834 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 17 August 2001 (17.08.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/226,347 18 August 2000 (18.08.2000) US (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): **PHARMACIA CORPORATION** [US/US]; Corporate Patent Department, 800 North Lindbergh Boulevard, St. Louis, MO 63167 (US).
- (72) Inventors; and (75) Inventors/Applicants (*for US only*): **KARALI, Tugrul, T.** [US/US]; 8335 N. Kildare, Skokie, IL 60076 (US). **KONTNY, Mark, J.** [US/US]; 2343 Huntington Lakes Drive, Libertyville, IL 60048 (US). **LE, Tang, T.** [US/US]; 1802 Oslo Court, Mundelein, IL 60060 (US).
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 02/15886 A2

(54) Title: ORAL FAST-MELT DOSAGE FORM OF A CYCLOOXYGENASE-2 INHIBITOR

(57) Abstract: A process is provided for preparing an oral fast-melt composition of a selective cyclooxygenase-2 inhibitory drug comprising (a) a step of wet granulating the selective cyclooxygenase-2 inhibitory drug together with a binding agent selected from gums, polypeptides, natural and modified starches, cellulosic materials, alginic acid and salts thereof, polyethylene glycol, polyvinylpyrrolidone, polymethacrylates, silicate salts and bentonites, and (b) a step of blending with the drug a saccharide of low moldability, wherein the above steps (a) and (b) occur in any order or simultaneously to result in formation of granules. Optionally the process further comprises (c) a step of blending the granules with at least one of a lubricant, a sweetening agent and a flavoring agent to form a tableting blend, and (d) a step of compressing the tableting blend to form oral fast-melt tablets. Also provided is a composition prepared by such a process.


ORAL FAST-MELT DOSAGE FORM OF A CYCLOOXYGENASE-2 INHIBITOR

FIELD OF THE INVENTION


The present invention relates to orally deliverable pharmaceutical compositions containing a selective cyclooxygenase-2 inhibitory drug, to processes for preparing such compositions, to methods of treatment comprising orally administering such compositions to a subject in need thereof, and to the use of such compositions in the manufacture of medicaments.

BACKGROUND OF THE INVENTION

Numerous compounds have been reported having therapeutically and/or prophylactically useful selective cyclooxygenase-2 inhibitory effect, and have been disclosed as having utility in treatment or prevention of specific cyclooxygenase-2 mediated disorders or of such disorders in general. Among such compounds are a large number of substituted pyrazolyl benzenesulfonamides as reported in U.S. Patent No. 5,760,068 to Talley *et al.*, including for example the compound 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, also referred to herein as celecoxib (I), and the compound 4-[5-(3-fluoro-4-methoxyphenyl)-3-difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, also referred to herein as deracoxib (II).




(I)




(II)

Other compounds reported to have therapeutically and/or prophylactically useful selective cyclooxygenase-2 inhibitory effect are substituted isoxazolyl benzenesulfonamides as reported in U.S. Patent No. 5,633,272 to Talley *et al.*, including for example the compound 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide, also referred to herein as valdecoxib (III).




Still other compounds reported to have therapeutically and/or prophylactically useful selective cyclooxygenase-2 inhibitory effect are substituted (methylsulfonyl)phenyl furanones as reported in U.S. Patent No. 5,474,995 to

- 5 Ducharme *et al.*, including for example the compound 3-phenyl-4-[4-(methylsulfonyl)phenyl]-5H-furan-2-one, also referred to herein as rofecoxib (IV).



U.S. Patent No. 5,981,576 to Belley *et al.* discloses a further series of (methylsulfonyl)phenyl furanones said to be useful as selective cyclooxygenase-2 inhibitory drugs, including 3-(1-cyclopropylmethoxy)-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]-5H-furan-2-one and 3-(1-cyclopropylethoxy)-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]-5H-furan-2-one.


- U.S. Patent No. 5,861,419 to Dube *et al.* discloses substituted pyridines said to be useful as selective cyclooxygenase-2 inhibitory drugs, including for example the compound 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine, also referred to herein as etoricoxib (V).



(V)

European Patent Application No. 0 863 134 discloses the compound 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one said to be useful as a selective cyclooxygenase-2 inhibitory drug.

- 5 U.S. Patent No. 6,034,256 to Carter *et al.* discloses a series of benzopyrans said to be useful as selective cyclooxygenase-2 inhibitory drugs, including the compound (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid (VI).



(VI)

- 10 International Patent Publication No. WO 00/24719 discloses substituted pyridazinones said to be useful as selective cyclooxygenase-2 inhibitory drugs, including the compound 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3-(2H)-pyridazinone.

- 15 A need for formulated compositions of selective cyclooxygenase-2 inhibitory drugs, in particular, easy-to-swallow compositions, exists. Easy-to-swallow drug delivery systems can provide many benefits over conventional dosage forms, particularly to populations such as the elderly, young children and other groups of patients that have difficulty swallowing conventional oral preparations.

- 20 Common oral forms such as tablets, pills or capsules generally must be swallowed with water. Many pediatric and elderly patients with weak swallowing ability are unwilling or unable to swallow such dosage forms.

Powders and granules are additional commonly used oral dosage forms.

However, these formulations can be difficult to swallow completely due to their tendency to remain in the oral cavity. In some instances, patients taking powdered dosage forms will feel choked with powder or feel pain or unpleasantness due to granules being lodged under dentures. Additionally, powders and granules typically
5 can only be used after the tearing or breaking of a package, tasks that elderly patients often find difficult to perform.

Further, powder and granule dosage forms are inconvenient to take as they typically must be diluted with a suitable amount of water or other liquid carrier prior to ingestion. This is particularly problematic when the medication is needed to
10 provide fast relief of pain, since water is not always readily obtainable throughout the day. Moreover, powders or granules taken after dissolution or suspension in a liquid can also be difficult for elderly patients suffering from incontinence as such patients may experience urination problems at night when relatively large volumes of liquid-based medications are taken before bedtime.

Syrups and elixirs are additional commonly used oral dosage forms. However,
15 elderly patients and others who have difficulty in measuring precise volumes are unlikely to be able to administer to themselves a proper dose and therefore require assistance at each administration.

International Patent Publication No. WO 00/32189, incorporated herein by
20 reference, discloses various oral preparations of celecoxib. However, easy-to-swallow preparations of compositions containing selective cyclooxygenase-2 inhibitory drugs have not been disclosed.

In light of the expanding elderly population, it is becoming critically important to develop safe, effective, easy-to-swallow pharmaceutical preparations to treat age-
25 related indications, wherein such preparations are convenient for elderly patients to self-administer and ingest.

U.S. Patent No. 5,576,014, incorporated herein by reference, discloses an intrabuccally dissolving compressed molding prepared by a wet granulation process wherein a low moldability saccharide is granulated with a high moldability saccharide
30 to form a granulate, which is then compressed into a molding. The resulting molding can incorporate a drug and is said to show quick disintegration and dissolution in the buccal cavity but to maintain sufficient hardness so as not break during production

and distribution. The compressed molding of U.S. Patent No. 5,576,014 is a type of dosage form known as a "fast-melt tablet", exhibiting rapid disintegration, usually associated with the carrier materials, typically sugars, and concomitant rapid dissolution or dispersion of the drug in the mouth, usually without need for water
5 other than that contained in saliva. A drug formulated in such a tablet is readily swallowed.

The term "fast-melt" as used herein refers to a composition such as a tablet wherein an active agent or drug is distributed or dispersed in a matrix formed by a carrier that, upon oral administration to a subject, disintegrates in the oral cavity,
10 thereby releasing the drug, typically in particulate form, for entry to the gastrointestinal tract by swallowing, and subsequent absorption. The term "oral cavity" includes the entire interior of the mouth, including not only the buccal cavity (that part of the oral cavity anterior to the teeth and gums) but also the sublingual and supralingual spaces.

15 With respect to drugs requiring a high dose for therapeutic effectiveness, the large size of a fast-melt tablet required to provide a therapeutic dose may be a limiting factor. To reduce tablet size, drug loading can be increased in a given formulation. However, typical fast-melt tablet formulations begin to lose their rapid disintegration characteristics as the relative amount of active agent in the tablet increases, at least in
20 part because of the corresponding reduction in the amount of readily soluble and/or disintegratable carrier. Alternatively, several tablets having a low drug loading would have to be ingested, which can result in patient inconvenience and decreased compliance.

However, selective cyclooxygenase-2 inhibitory drugs present certain
25 challenges for formulation as fast-melt tablets. For example, many selective cyclooxygenase-2 inhibitory compounds, including celecoxib, deracoxib, valdecoxib, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one, etoricoxib and rofecoxib, have very low solubility in aqueous media. In addition, some, for example celecoxib, have relatively high dose requirements. Celecoxib also presents
30 difficulties as a result of unique physical and chemical characteristics such as electrostatic and cohesive properties, low bulk density, low compressibility and poor flow properties. Due at least in part to these properties, celecoxib crystals tend to

segregate and agglomerate together during mixing, resulting in a non-uniformly blended composition containing undesirably large, insoluble aggregates of celecoxib.

It would be a much desired advance in the art to provide a fast-melt formulation of a selective cyclooxygenase-2 inhibitory drug of low solubility, such as celecoxib, that has the desired blend uniformity for rapid and complete disintegration in the mouth.

SUMMARY OF THE INVENTION

According to the present invention, there is now provided a process for preparing an oral fast-melt composition of a selective cyclooxygenase-2 inhibitory drug comprising (a) a step of wet granulating the selective cyclooxygenase-2 inhibitory drug together with a binding agent selected from gums, polypeptides, natural and modified starches, cellulosic materials, alginic acid and salts thereof, polyethylene glycol, polyvinylpyrrolidone, polymethacrylates, silicate salts and bentonites, and (b) a step of blending with the drug a saccharide of low moldability, wherein the above steps (a) and (b) occur in any order or simultaneously to result in formation of granules.

The term "low moldability" as applied to a saccharide herein refers, in accordance with above-cited U.S. Patent No. 5,576,014, to a saccharide which generally shows a hardness of less than 2 kp when 150 mg of the saccharide is made into a tablet using a punch of 8 mm in diameter under a pressure of 10 to 50 kg/cm². Thus a saccharide of low moldability as required herein can be, for example, a "non-direct compression sugar" as defined in U.S. Patent No. 6,024,981 to Khankari *et al.*, the disclosure of which is incorporated herein by reference. In particular, a saccharide of low moldability typically has a fine particle size, for example an average particle size of about 10 μ m to about 80 μ m, and is not pre-granulated. Above-cited U.S. Patent No. 6,024,981 discloses that it is well known in the pharmaceutical industry that decreasing the particle size of a sugar decreases its compressibility and fluidity. Not all saccharides, even at fine particle size, are "non-direct compression sugars" or saccharides of low moldability as required herein. Examples of saccharides of low moldability, at least when in finely particulate form without pre-granulation, include lactose, mannitol, glucose, sucrose, xylitol, *etc.*

In a presently preferred embodiment, a process of the invention comprises wet

granulation of a selective cyclooxygenase-2 inhibitory drug together with a saccharide of low moldability and a binding agent as specified herein.

In another embodiment, a process of the invention comprises a step of blending a selective cyclooxygenase-2 inhibitory drug with a saccharide of low
5 moldability, followed by a step of wet granulating the resulting blend with a binding agent as specified herein.

In still another preferred embodiment, a process of the invention comprises wet granulation of a saccharide having low moldability with a binding agent as specified herein to obtain granules of a first kind, wet granulation of a selective
10 cyclooxygenase-2 inhibitory drug together with a binding agent as specified herein to obtain granules of a second kind, and admixing the granules of said first and second kinds.

An especially preferred process of the invention further comprises a step of compressing the wet granulated, for example fluid bed granulated, composition
15 prepared by any of the processes summarized above to produce a solid dosage form, for example an oral fast-melt tablet.

An oral fast-melt composition having a selective cyclooxygenase-2 inhibitory drug dispersed in a matrix comprising a saccharide of low moldability and a binding agent selected from gums, polypeptides, natural and modified starches, cellulosic
20 materials, alginic acid and salts thereof, polyethylene glycol, polyvinylpyrrolidone, polymethacrylates, silicate salts and bentonites, is a further embodiment of the present invention. A preferred composition of this embodiment is an oral fast-melt tablet. A still further embodiment is an oral fast-melt composition, for example, an oral fast-melt tablet, prepared by a process as herein described.

Preferred tablets of the invention disintegrate within about 30 to about 150
25 seconds after placement in a standard *in vitro* disintegration assay (e.g., conducted according to U.S. Pharmacopeia 24 (2000), Test No. 701) and/or disintegrate within about 5 to about 60 seconds after placement in the oral cavity of a subject. Preferably, such tablets have a hardness of about 1 kp to about 10 kp.

Processes of the present invention have been found to resolve at least some of
30 the difficulties alluded to above in a surprisingly effective manner. Thus, in a significant advance in the art, a selective cyclooxygenase-2 inhibitory drug of low

water solubility is now presented in a novel, easy-to-swallow, fast-melt formulation. A particular advantage of processes of the invention is that oral fast-melt tablets containing a cyclooxygenase-2 inhibitory drug of low water solubility, even such a drug having a relatively high dosage requirement, for example celecoxib, can be
5 prepared by fluid bed granulation and compression. These oral fast-melt tablets provide a heretofore nonexistent dosage form of a selective cyclooxygenase-2 inhibitory drug that is efficient to produce, convenient and easy to swallow.

Also provided by the present invention are methods for therapeutic and/or prophylactic use of compositions of the present invention, and a method of use of a
10 composition of the invention for preparing a medicament. Other features of this invention will be in part apparent and in part pointed out hereinafter.


DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a process for preparing an intraorally disintegrating pharmaceutical composition, *i.e.*, an oral fast-melt composition, of a
15 selective cyclooxygenase-2 inhibitory drug. The process comprises a step of wet granulating the drug together with a binding agent selected from gums, polypeptides, natural and modified starches, cellulosic materials, alginic acid and salts thereof, polyethylene glycol, polyvinylpyrrolidone, polymethacrylates, silicate salts and bentonites, and a step of blending with the drug a saccharide of low moldability. The
20 wet granulating step and the blending step can take place in any order or simultaneously to form granules. Compositions prepared by such a process represent an embodiment of the present invention.

A further embodiment of the invention is an intraorally disintegrating pharmaceutical composition comprising a selective cyclooxygenase-2 inhibitory drug
25 of low water solubility dispersed in a matrix comprising a saccharide having low moldability and a binding agent selected from gums, polypeptides, natural and modified starches, cellulosic materials, alginic acid and salts thereof, polyethylene glycol, polyvinylpyrrolidone, polymethacrylates, silicate salts and bentonites. In this embodiment, the process by which the composition is prepared is immaterial so long
30 as the drug is dispersed in the matrix as described.

Processes and compositions of the invention are especially useful for selective cyclooxygenase-2 inhibitory compounds having solubility in water lower than about

1 mg/ml. In particular, processes and compositions of the invention are suitable for compounds having the formula (VII):



- where R^3 is a methyl or amino group, R^4 is hydrogen or a C_{1-4} alkyl or alkoxy group,
 5 X is N or CR^5 where R^5 is hydrogen or halogen, and Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl or halomethyl groups. Preferred such five- to six-membered rings are cyclopentenone, furanone, methylpyrazole, isoxazole and pyridine rings substituted at no more than
 10 one position.

- Illustratively, processes and compositions of the invention are suitable for celecoxib, deracoxib, valdecoxib, rofecoxib, etoricoxib, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one, (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid and 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-
 15 methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3-(2H)-pyridazinone, more particularly celecoxib, valdecoxib, rofecoxib and etoricoxib, and still more particularly celecoxib and valdecoxib.

- The invention is illustrated herein with particular reference to celecoxib, and it will be understood that any other selective cyclooxygenase-2 inhibitory compound of
 20 low solubility in water can, if desired, be substituted in whole or in part for celecoxib in processes and compositions herein described.

- Celecoxib used in the process and compositions of the present invention can be prepared by a process known *per se*, for example by processes set forth in U.S. Patent No. 5,466,823 to Talley *et al.* or in U.S. Patent No. 5,892,053 to Zhi & Newaz,
 25 both incorporated herein by reference. Other selective cyclooxygenase-2 inhibitory drugs can be prepared by processes known *per se*, including processes set forth in patent publications disclosing such drugs; for example in the case of valdecoxib in

above-cited U.S. Patent No. 5,633,272, and in the case of rofecoxib in above-cited U.S. Patent No. 5,474,995.

Celecoxib compositions of the present invention preferably comprise celecoxib in a daily dosage amount of about 10 mg to about 1000 mg, more preferably
5 about 25 mg to about 400 mg, and most preferably about 50 mg to about 200 mg.

For other selective cyclooxygenase-2 inhibitory drugs, a daily dosage amount can be in a range known to be therapeutically effective for such drugs. Preferably, the daily dosage amount is in a range providing therapeutic equivalence to celecoxib in the daily dosage ranges indicated immediately above.

10 Dosage units of celecoxib compositions of the invention typically contain about 10 mg to about 400 mg of celecoxib, for example, a 10, 20, 37.5, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350 or 400 mg dose of celecoxib. Preferred dosage units contain about 25 mg to about 400 mg of celecoxib. More preferred dosage unit forms contain about 50 mg to about 200 mg of celecoxib. A particular dosage unit
15 can be selected to accommodate the desired frequency of administration used to achieve a specified daily dosage. The amount of the unit dosage form of the composition that is administered and the dosage regimen for treating the condition or disorder will depend on a variety of factors, including the age, weight, sex and medical condition of the subject, the severity of the condition or disorder, the route
20 and frequency of administration, and the particular selective cyclooxygenase-2 inhibitory drug selected, and thus may vary widely. It is contemplated, however, that for most purposes a once-a-day or twice-a-day administration regimen provides the desired therapeutic efficacy.

In a celecoxib composition, celecoxib can be present in the composition at a
25 minimum concentration of about 1%, preferably about 4%, more preferably about 10%, and still more preferably about 20%, by weight. Where the selective cyclooxygenase-2 inhibitory drug is therapeutically effective at lower dosages than celecoxib, the minimum concentration can be lower than that indicated immediately above for celecoxib; for example in the case of valdecoxib the drug can be present at a
30 minimum concentration of about 0.1% by weight. Celecoxib can be present in the composition at a maximum concentration of about 60%, more typically about 50%, by weight.

Thus typically the selective cyclooxygenase-2 inhibitory drug is present in an amount of about 0.1% to about 60%, more preferably in an amount of about 1% to about 60%, still more preferably in an amount of about 4% to about 60%, still more preferably in an amount of about 10% to about 60%, and most preferably in an amount of about 20% to about 60%, for example about 50%, by weight of the composition.

Compositions of the present invention are useful in treatment and prevention of a very wide range of disorders mediated by cyclooxygenase-2 (COX-2), including but not restricted to disorders characterized by inflammation, pain and/or fever. Such compositions are especially useful as anti-inflammatory agents, such as in treatment of arthritis, with the additional benefit of having significantly less harmful side effects than compositions of conventional nonsteroidal anti-inflammatory drugs (NSAIDs) that lack selectivity for COX-2 over COX-1. In particular, such compositions have reduced potential for gastrointestinal toxicity and gastrointestinal irritation including upper gastrointestinal ulceration and bleeding, reduced potential for renal side effects such as reduction in renal function leading to fluid retention and exacerbation of hypertension, reduced effect on bleeding times including inhibition of platelet function, and possibly a lessened ability to induce asthma attacks in aspirin-sensitive asthmatic subjects, by comparison with compositions of conventional NSAIDs. Thus compositions of the invention comprising a selective COX-2 inhibitory drug are particularly useful as an alternative to conventional NSAIDs where such NSAIDs are contraindicated, for example in patients with peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of gastrointestinal lesions; gastrointestinal bleeding, coagulation disorders including anemia such as hypoprothrombinemia, hemophilia or other bleeding problems; kidney disease; or in patients prior to surgery or patients taking anticoagulants.

Such compositions are useful to treat arthritic disorders, including but not limited to rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis.

Such compositions are also useful in treatment of asthma, bronchitis, menstrual cramps, preterm labor, tendinitis, bursitis, allergic neuritis, cytomegalovirus infectivity, apoptosis including HIV-induced apoptosis, lumbago, liver disease

including hepatitis, skin-related conditions such as psoriasis, eczema, acne, burns, dermatitis and ultraviolet radiation damage including sunburn, and post-operative inflammation including that following ophthalmic surgery such as cataract surgery or refractive surgery.

- 5 Such compositions are useful to treat gastrointestinal conditions such as inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis.

- Such compositions are useful in treating inflammation in such diseases as migraine headaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's
10 disease, sclerodoma, rheumatic fever, type I diabetes, neuromuscular junction disease including myasthenia gravis, white matter disease including multiple sclerosis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, nephritis, hypersensitivity, swelling occurring after injury including brain edema, myocardial ischemia, and the like.

- 15 Such compositions are useful in treatment of ophthalmic diseases, such as retinitis, scleritis, episcleritis, conjunctivitis, retinopathies, uveitis, ocular photophobia, and of acute injury to eye tissue.

- Such compositions are useful in treatment of pulmonary inflammation, such as that associated with viral infections and cystic fibrosis, and in bone resorption such as
20 that associated with osteoporosis.

- Such compositions are useful for treatment of certain central nervous system disorders, such as cortical dementias including Alzheimer's disease, neurodegeneration, and central nervous system damage resulting from stroke, ischemia and trauma. The term "treatment" in the present context includes partial or
25 total inhibition of dementias, including Alzheimer's disease, vascular dementia, multi-infarct dementia, pre-senile dementia, alcoholic dementia and senile dementia.

 Such compositions are useful in treatment of allergic rhinitis, respiratory distress syndrome, endotoxin shock syndrome and liver disease.

- Such compositions are useful in treatment of pain, including but not limited to
30 postoperative pain, dental pain, muscular pain, and pain resulting from cancer. For example, such compositions are useful for relief of pain, fever and inflammation in a variety of conditions including rheumatic fever, influenza and other viral infections

including common cold, low back and neck pain, dysmenorrhea, headache, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns, and trauma following surgical and dental procedures.

- 5 Such compositions are useful for, but not limited to, treating and preventing inflammation-related cardiovascular disorders in a subject. Such compositions are useful for treatment and prevention of vascular diseases, coronary artery disease, aneurysm, vascular rejection, arteriosclerosis, atherosclerosis including cardiac transplant atherosclerosis, myocardial infarction, embolism, stroke, thrombosis
- 10 including venous thrombosis, angina including unstable angina, coronary plaque inflammation, bacterial-induced inflammation including Chlamydia-induced inflammation, viral induced inflammation, and inflammation associated with surgical procedures such as vascular grafting including coronary artery bypass surgery, revascularization procedures including angioplasty, stent placement, endarterectomy,
- 15 or other invasive procedures involving arteries, veins and capillaries.

- Such compositions are useful for, but not limited to, treatment of angiogenesis-related disorders in a subject, for example to inhibit tumor angiogenesis. Such compositions are useful for treatment of neoplasia, including metastasis; ophthalmological conditions such as corneal graft rejection, ocular neovascularization,
- 20 retinal neovascularization including neovascularization following injury or infection, diabetic retinopathy, macular degeneration, retrolental fibroplasia and glaucoma, including neovascular glaucoma; ulcerative diseases such as gastric ulcer; pathological, but non-malignant, conditions such as hemangiomas, including infantile hemangiomas, angiofibroma of the nasopharynx and avascular necrosis of bone; and
- 25 disorders of the female reproductive system such as endometriosis.

- Such compositions are useful for prevention or treatment of benign and malignant tumors/neoplasia including cancers, for example colorectal cancer, brain cancer, bone cancer, epithelial cell-derived neoplasia (epithelial carcinoma) such as basal cell carcinoma, adenocarcinoma, gastrointestinal cancer such as lip cancer,
- 30 mouth cancer, esophageal cancer, small bowel cancer, stomach cancer, colon cancer, liver cancer, bladder cancer, pancreas cancer, ovary cancer, cervical cancer, lung cancer, breast cancer and skin cancer, such as squamous cell and basal cell cancers,

prostate cancer, renal cell carcinoma, and other known cancers that affect epithelial cells throughout the body. Neoplasias for treatment of which compositions of the invention are contemplated to be particularly useful are gastrointestinal cancer, Barrett's esophagus, liver cancer, bladder cancer, pancreas cancer, ovary cancer,

5 prostate cancer, cervical cancer, lung cancer, breast cancer and skin cancer, such as squamous cell and basal cell cancers. Compositions of the invention can also be used to treat fibrosis that occurs with radiation therapy. Such compositions can be used to treat subjects having adenomatous polyps, including those with familial adenomatous polyposis (FAP). Additionally, such compositions can be used to prevent polyps from

10 forming in patients at risk of FAP.

Such compositions inhibit prostanoid-induced smooth muscle contraction by preventing synthesis of contractile prostanoids and hence can be of use in treatment of dysmenorrhea, premature labor, asthma and eosinophil-related disorders. They also can be of use for decreasing bone loss particularly in postmenopausal women (*i.e.*,

15 treatment of osteoporosis), and for treatment of glaucoma.

Preferred uses for compositions of the present invention are for treatment of rheumatoid arthritis and osteoarthritis, for pain management generally (particularly post-oral surgery pain, post-general surgery pain, post-orthopedic surgery pain, and acute flares of osteoarthritis), for treatment of Alzheimer's disease, and for colon

20 cancer chemoprevention.

For treatment of rheumatoid arthritis or osteoarthritis, such compositions of the invention can be used to provide a daily dosage of celecoxib of about 50 mg to about 1000 mg, preferably about 100 mg to about 600 mg, more preferably about 150 mg to about 500 mg, still more preferably about 175 mg to about 400 mg, for example

25 about 200 mg. A daily dose of celecoxib of about 0.7 to about 13 mg/kg body weight, preferably about 1.3 to about 8 mg/kg body weight, more preferably about 2 to about 6.7 mg/kg body weight, and still more preferably about 2.3 to about 5.3 mg/kg body weight, for example about 2.7 mg/kg body weight, is generally appropriate when administered in a composition of the invention. The daily dose can be administered in

30 one to about four doses per day, preferably one or two doses per day.

For treatment of Alzheimer's disease or cancer, such compositions of the invention can be used to provide a daily dosage of celecoxib of about 50 mg to about

1000 mg, preferably about 100 mg to about 800 mg, more preferably about 150 mg to about 600 mg, and still more preferably about 175 mg to about 400 mg, for example about 400 mg. A daily dose of about 0.7 to about 13 mg/kg body weight, preferably about 1.3 to about 10.7 mg/kg body weight, more preferably about 2 to about 8 mg/kg
5 body weight, and still more preferably about 2.3 to about 5.3 mg/kg body weight, for example about 5.3 mg/kg body weight, is generally appropriate when administered in a composition of the invention. The daily dose can be administered in one to about four doses per day, preferably one or two doses per day.

For pain management generally and specifically for treatment and prevention
10 of headache and migraine, such compositions of the invention can be used to provide a daily dosage of celecoxib of about 50 mg to about 1000 mg, preferably about 100 mg to about 600 mg, more preferably about 150 mg to about 500 mg, and still more preferably about 175 mg to about 400 mg, for example about 200 mg. A daily dose of celecoxib of about 0.7 to about 13 mg/kg body weight, preferably about 1.3 to about 8
15 mg/kg body weight, more preferably about 2 to about 6.7 mg/kg body weight, and still more preferably about 2.3 to about 5.3 mg/kg body weight, for example about 2.7 mg/kg body weight, is generally appropriate when administered in a composition of the invention. The daily dose can be administered in one to about four doses per day. Administration at a rate of one 50 mg dose unit four times a day, one 100 mg dose
20 unit or two 50 mg dose units twice a day or one 200 mg dose unit, two 100 mg dose units or four 50 mg dose units once a day is preferred.

Besides being useful for human treatment, compositions of the invention are also useful for veterinary treatment of companion animals, exotic animals, farm animals, and the like, particularly mammals including rodents. More particularly,
25 compositions of the invention are useful for veterinary treatment of cyclooxygenase-2 mediated disorders in horses, dogs and cats.

The present invention also is directed to a therapeutic method of treating a condition or disorder where treatment with a cyclooxygenase-2 inhibitory drug is indicated, the method comprising oral administration of one or more pharmaceutical
30 compositions of the present invention to a patient in need thereof. The dosage regimen to prevent, give relief from, or ameliorate the condition or disorder preferably corresponds to once-a-day or twice-a-day treatment, but can be modified in

accordance with a variety of factors. These include the type, age, weight, sex, diet and medical condition of the patient and the nature and severity of the disorder. Thus, the dosage regimen actually employed can vary widely and can therefore deviate from the preferred dosage regimens set forth above.

5 Initial treatment of a patient suffering from a condition or disorder where treatment with a cyclooxygenase-2 inhibitory drug is indicated can begin with a dose regimen as indicated above. Treatment is generally continued as necessary over a period of several weeks to several months or years until the condition or disorder has been controlled or eliminated. Patients undergoing treatment with a composition of
10 the invention can be routinely monitored by any of the methods well known in the art to determine the effectiveness of therapy. Continuous analysis of data from such monitoring permits modification of the treatment regimen during therapy so that optimally effective amounts of the drug are administered at any point in time, and so that the duration of treatment can be determined. In this way, the treatment regimen
15 and dosing schedule can be rationally modified over the course of therapy so that the lowest amount of the drug exhibiting satisfactory effectiveness is administered, and so that administration is continued only for so long as is necessary to successfully treat the condition or disorder.

The present compositions can be used in combination therapies with opioids
20 and other analgesics, including narcotic analgesics, Mu receptor antagonists, Kappa receptor antagonists, non-narcotic (i.e. non-addictive) analgesics, monamine uptake inhibitors, adenosine regulating agents, cannabinoid derivatives, Substance P antagonists, neurokinin-1 receptor antagonists and sodium channel blockers, among others. Preferred combination therapies comprise use of a composition of the
25 invention with one or more compounds selected from aceclofenac, acetaminin, *e*-acetamidocaproic acid, acetaminophen, acetaminosalol, acetanilide, acetylsalicylic acid (aspirin), *S*-adenosylmethionine, alclofenac, alfentanil, allylprodine, alminoprofen, aloxiprin, alphaprodine, aluminum bis(acetylsalicylate), amfenac, aminochlorthenoxazin, 3-amino-4-hydroxybutyric acid, 2-amino-4-picoline,
30 aminopropyl, aminopyrine, amixetrine, ammonium salicylate, ampiroxicam, antolmetin guacil, anileridine, antipyrine, antipyrine salicylate, antrafenine, apazone, bendazac, benorylate, benoxaprofen, benzpiperylon, benzydamine, benzylmorphine,

- bermopropfen, bezitramide, α -bisabolol, bromfenac, *p*-bromoacetanilide,
5-bromosalicylic acid acetate, bromosaligenin, bucetin, bucloxic acid, bucolome,
bufexamac, bumadizon, buprenorphine, butacetin, butibufen, butophanol, calcium
acetylsalicylate, carbamazepine, carbiphen, carprofen, carsalam, chlorobutanol,
5 chlorthenoxazin, choline salicylate, cinchophen, cinmetacin, ciramadol, clidanac,
clometacin, clonitazene, clonixin, clopirac, clove, codeine, codeine methyl bromide,
codeine phosphate, codeine sulfate, cropropamide, crotethamide, desomorphine,
dexodrol, dextromoramide, dezocine, diampromide, diclofenac sodium,
difenamizole, difenpiramide, diflunisal, dihydrocodeine, dihydrocodeinone enol
10 acetate, dihydromorphine, dihydroxyaluminum acetylsalicylate, dimenoxadol,
dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, diprocetyl,
dipyron, ditazol, droxicam, emorfazone, enfenamic acid, epirizole, eptazocine,
etersalate, ethenzamide, ethoheptazine, ethoxazene, ethylmethylthiambutene,
ethylmorphine, etodolac, etofenamate, etonitazene, eugenol, felbinac, fenbufen,
15 fenclozic acid, fendosal, fenopropfen, fentanyl, fentiazac, fepradinol, feprazone,
floctafenine, flufenamic acid, flunoxaprofen, fluoresone, flupirtine, fluproquazone,
flurbiprofen, fosfosal, gentisic acid, glafenine, glucametacin, glycol salicylate,
guaiazulene, hydrocodone, hydromorphone, hydroxypethidine, ibufenac, ibuprofen,
ibuproxam, imidazole salicylate, indomethacin, indoprofen, isofezolac, isoladol,
20 isomethadone, isonixin, isoxepac, isoxicam, ketobemidone, ketoprofen, ketorolac,
p-lactophenetide, lefetamine, levorphanol, lofantanil, lonazolac, lornoxicam,
loxoprofen, lysine acetylsalicylate, magnesium acetylsalicylate, meclofenamic acid,
mefenamic acid, meperidine, meptazinol, mesalamine, metazocine, methadone
hydrochloride, methotrimeprazine, metiazinic acid, metofoline, metopon,
25 mofebutazone, mofezolac, morazone, morphine, morphine hydrochloride, morphine
sulfate, morpholine salicylate, myrophine, nabumetone, nalbuphine, 1-naphthyl
salicylate, naproxen, narceine, nefopam, nicomorphine, nifenazone, niflumic acid,
nimesulide, 5'-nitro-2'-propoxyacetanilide, norlevorphanol, normethadone,
normorphine, norpipanone, olsalazine, opium, oxaceprol, oxametacine, oxaprozin,
30 oxycodone, oxymorphone, oxyphenbutazone, papaveretum, paranyline, parsalimide,
pentazocine, perisoxal, phenacetin, phenadoxone, phenazocine, phenazopyridine
hydrochloride, phenocoll, phenoperidine, phenopyrazone, phenyl acetylsalicylate,

phenylbutazone, phenyl salicylate, phenylramidol, piketoprofen, piminodine, pipebuzone, piperylone, pirofen, pirazolac, piritramide, piroxicam, pranoprofen, proglumetacin, proheptazine, promedol, propacetamol, propiram, propoxyphene, propyphenazone, proquazone, protizinic acid, ramifenazone, remifentanyl, rimazolium

5 metilsulfate, salacetamide, salicin, salicylamide, salicylamide *o*-acetic acid, salicylsulfuric acid, salsalte, salverine, simetride, sodium salicylate, sufentanyl, sulfasalazine, sulindac, superoxide dismutase, suprofen, suxibuzone, talniflumate, tenidap, tenoxicam, terofenamate, tetrandrine, thiazolinobutazone, tiaprofenic acid, tiaramide, tilidine, tinoridine, tolfenamic acid, tolmetin, tramadol, tropesin, viminol,

10 xenbucin, ximoprofen, zaltoprofen and zomepirac (see The Merck Index, 12th Edition (1996), Therapeutic Category and Biological Activity Index, lists therein headed "Analgesic", "Anti-inflammatory" and "Antipyretic").

Particularly preferred combination therapies comprise use of a composition of the invention, for example a celecoxib or valdecoxib composition of the invention,

15 with an opioid compound, more particularly where the opioid compound is codeine, meperidine, morphine or a derivative thereof.

The compound to be administered in combination with celecoxib can be formulated separately from the celecoxib or co-formulated with the celecoxib in a composition of the invention. Where celecoxib is co-formulated with a second drug,

20 for example an opioid drug, the second drug can be formulated in immediate-release, rapid-onset, sustained-release or dual-release form.

In an embodiment of the invention, particularly where the cyclooxygenase-2 mediated condition is headache or migraine, the present selective cyclooxygenase-2 inhibitory drug composition is administered in combination therapy with a

25 vasomodulator, preferably a xanthine derivative having vasomodulatory effect, more preferably an alkylxanthine compound.

Combination therapies wherein an alkylxanthine compound is co-administered with a selective cyclooxygenase-2 inhibitory drug composition as provided herein are embraced by the present embodiment of the invention whether or not the

30 alkylxanthine is a vasomodulator and whether or not the therapeutic effectiveness of the combination is to any degree attributable to a vasomodulatory effect. The term "alkylxanthine" herein embraces xanthine derivatives having one or more C₁₋₄ alkyl,

preferably methyl, substituents, and pharmaceutically acceptable salts of such xanthine derivatives. Dimethylxanthines and trimethylxanthines, including caffeine, theobromine and theophylline, are especially preferred. Most preferably, the alkylxanthine compound is caffeine.

- 5 The total and relative dosage amounts of the selective cyclooxygenase-2 inhibitory drug and of the vasomodulator or alkylxanthine are selected to be therapeutically and/or prophylactically effective for relief of pain associated with the headache or migraine. Suitable dosage amounts will depend on the particular selective cyclooxygenase-2 inhibitory drug and the particular vasomodulator or
- 10 alkylxanthine selected. For example, in a combination therapy with celecoxib and caffeine, typically the celecoxib will be administered in a daily dosage amount of about 50 mg to about 1000 mg, preferably about 100 mg to about 600 mg, and the caffeine in a daily dosage amount of about 1 mg to about 500 mg, preferably about 10 mg to about 400 mg, more preferably about 20 mg to about 300 mg.

- 15 The vasomodulator or alkylxanthine component of the combination therapy can be administered in any suitable dosage form by any suitable route, preferably orally. The vasomodulator or alkylxanthine can optionally be coformulated with the selective cyclooxygenase-2 inhibitory drug in the composition of the invention. Thus an oral fast-melt composition of the invention optionally comprises both an
- 20 aminosulfonyl-comprising selective cyclooxygenase-2 inhibitory drug and a vasomodulator or alkylxanthine such as caffeine, in total and relative amounts consistent with the dosage amounts set out hereinabove.

- The phrase "in total and relative amounts effective to relieve pain", with respect to amounts of a selective cyclooxygenase-2 inhibitory drug and a
- 25 vasomodulator or alkylxanthine in a composition of the present embodiment, means that these amounts are such that (a) together these components are effective to relieve pain, and (b) each component is or would be capable of contribution to a pain-relieving effect if the other component is or were not present in so great an amount as to obviate such contribution.

- 30 A composition of the invention comprises as active ingredient a selective cyclooxygenase-2 inhibitory drug as hereinabove described, and various pharmaceutically acceptable excipients. Excipients that must be present are a

saccharide having low moldability as herein defined, and a binding agent as herein defined. Optionally, a composition of the invention can contain one or more additional pharmaceutically acceptable excipients including, but not limited to, wetting agents, water-soluble lubricants, water-insoluble lubricants, disintegrants, 5 glidants, sweeteners, flavoring agents, colorants, *etc.* Such optional additional components should be physically and chemically compatible with the other ingredients of the composition and must not be deleterious to the recipient.

Presently preferred low moldability saccharides include lactose and mannitol, particularly mannitol in its non-direct compression or powder form as described in 10 Handbook of Pharmaceutical Excipients, 3rd Ed. (2000), Pharmaceutical Press, pp. 324-328. One or more low moldability saccharides are present in compositions of the invention in a total amount of about 10% to about 90%, preferably about 15% to about 60%, and more preferably about 25% to about 50%, for example about 40%, by weight of the composition.

15 The binding agent is selected from gums, polypeptides, natural and modified starches, cellulosic materials, alginic acid and salts thereof, agar, polyethylene glycol, polyvinylpyrrolidone, polymethacrylates, silicate salts and bentonites.

Preferred gums include acacia, carrageenan, guar, locust bean, karaya, tragacanth and xanthan gums. A preferred polypeptide is gelatin. Preferred starches 20 include corn starch and pregelatinized starch. Preferred cellulosic materials include microcrystalline cellulose, methylcellulose, ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose and salts thereof, *e.g.*, sodium carboxymethylcellulose. A preferred alginic acid salt is sodium alginate. A preferred silicate salt is magnesium aluminum silicate.

25 One or more binding agents are present in a total amount of about 1% to about 10%, preferably about 1% to about 7.5%, and more preferably about 1% to about 5%, by weight of the composition.

Compositions of the present invention optionally comprise one or more pharmaceutically acceptable wetting agents. Surfactants, hydrophilic polymers and 30 certain clays can be useful as wetting agents to aid in wetting of a hydrophobic drug, such as celecoxib, by the granulation fluid during wet granulation.

Non-limiting examples of surfactants that can be used as wetting agents in

compositions of the present invention include quaternary ammonium compounds, for example benzalkonium chloride, benzethonium chloride and cetylpyridinium chloride, dioctyl sodium sulfosuccinate, polyoxyethylene alkylphenyl ethers, for example nonoxynol 9, nonoxynol 10, and octoxynol 9, poloxamers (polyoxyethylene and

5 polyoxypropylene block copolymers), polyoxyethylene fatty acid glycerides and oils, for example polyoxyethylene (8) caprylic/capric mono- and diglycerides (*e.g.*, Labrasol™ of Gattefossé), polyoxyethylene (35) castor oil and polyoxyethylene (40) hydrogenated castor oil; polyoxyethylene alkyl ethers, for example polyoxyethylene (20) cetostearyl ether, polyoxyethylene fatty acid esters, for example polyoxyethylene

10 (40) stearate, polyoxyethylene sorbitan esters, for example polysorbate 20 and polysorbate 80 (*e.g.*, Tween™ 80 of ICI), propylene glycol fatty acid esters, for example propylene glycol laurate (*e.g.*, Lauroglycol™ of Gattefossé), sodium lauryl sulfate, fatty acids and salts thereof, for example oleic acid, sodium oleate and triethanolamine oleate, glyceryl fatty acid esters, for example glyceryl monostearate,

15 sorbitan esters, for example sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate and sorbitan monostearate, tyloxapol, and mixtures thereof. Sodium lauryl sulfate is a preferred wetting agent in compositions of the present invention.

One or more wetting agents, if desired, are present in compositions of the instant invention in a total amount of about 0.05% to about 5%, preferably about

20 0.075% to about 2.5%, and more preferably about 0.25% to about 1%, for example about 0.5%, by weight of the composition.

Compositions of the present invention optionally comprise one or more pharmaceutically acceptable lubricants as a carrier material. Suitable lubricants include, either individually or in combination, glyceryl behapate (*e.g.* Compritol™

25 888), stearates (magnesium, calcium, and sodium), stearic acid, hydrogenated vegetable oils (*e.g.*, Sterotex™), colloidal silica, talc, waxes, boric acid, sodium benzoate, sodium acetate, sodium fumarate, sodium chloride, DL-leucine, polyethylene glycols (*e.g.*, Carbowax™ 4000 and Carbowax™ 6000), and sodium oleate. Optionally a lubricant can be used in mixture with a wetting agent, as for

30 example in calcium stearate/sodium lauryl sulfate mixtures (*e.g.*, Sterowet™). Magnesium stearate, stearic acid and mixtures thereof are preferred lubricants.

One or more lubricants optionally are present in compositions of the present

invention in a total amount of about 0.05% to about 5%, preferably about 0.75% to about 2.5%, and more preferably about 1% to about 2%, for example, about 1.5%, by weight of the composition.

Compositions of the present invention optionally comprise one or more
5 pharmaceutically acceptable disintegrants, particularly for tablet formulations. However, the oral fast-melt tablets provided herein typically disintegrate rapidly in the oral cavity and have no requirement for added disintegrant. Suitable disintegrants, if desired, include, either individually or in combination, starches, sodium starch glycolate, clays (such as Veegum™ HV), celluloses (such as purified cellulose,
10 methylcellulose, sodium carboxymethylcellulose and carboxymethylcellulose), croscarmellose sodium, alginates, pregelatinized corn starches (such as National™ 1551 and National™ 1550), crospovidone, and gums (such as agar, guar, locust bean, karaya, pectin and tragacanth gums). Disintegrants may be added at any suitable step during the preparation of the composition, particularly prior to granulation or during a
15 blending step prior to tablet compression. Croscarmellose sodium and sodium starch glycolate are preferred disintegrants.

One or more disintegrants optionally are present in a total amount of about 0.5% to about 7.5%, preferably about 1% to about 5%, and more preferably about 1% to about 3.5%, by weight of the composition.

20 Optionally, an effervescent salt can be used as a disintegrant and to enhance organoleptic properties of a fast-melt tablet of the invention.

Compositions of the present invention optionally comprise one or more pharmaceutically acceptable glidants, for example talc or silicon dioxide, to enhance flow of tableting material into tablet dies, to prevent sticking of tableting material to
25 punches and dies, or to produce tablets having a sheen. Glidants may be added at any suitable step during preparation of the composition, particularly prior to granulation or during a blending step prior to tablet compression.

One or more glidants optionally are present in a total amount of about 0.05% to about 5%, preferably about 0.1% to about 2%, and more preferably about 0.25% to
30 about 1%, for example, about 0.5%, by weight of the composition.

Compositions of the present invention optionally comprise one or more pharmaceutically acceptable sweeteners. Non-limiting examples of sweeteners that

can be used in compositions of the present invention include mannitol, propylene glycol, sodium saccharin, acesulfame K, neotame, aspartame, *etc.*

Compositions of the present invention optionally comprise one or more pharmaceutically acceptable flavoring agents. Non-limiting examples of flavoring agents that can be used in compositions of the present invention include peppermint, 5 spearmint, grape, cherry, strawberry, lemon, *etc.*

In a preferred embodiment, compositions of the invention are in the form of discrete solid dosage units, most preferably tablets. Tablets of the invention can be made to any desired size, for example 8 mm, 10 mm, 12 mm, *etc.*, shape, for example 10 round, oval, oblong, *etc.*, weight, and thickness. Optionally, solid dosage units of the invention may have etchings or monograms on one or both sides.

Preferred tablet compositions of the invention disintegrate within about 30 to about 300 seconds, more preferably within about 30 to about 200 seconds, and still more preferably within about 30 to about 150 seconds, in a standard *in vitro* 15 disintegration assay (*e.g.*, conducted according to U.S. Pharmacopeia '24 (2000), Test No. 701).

Alternatively or additionally, preferred tablet compositions of the invention disintegrate within about 5 to about 60 seconds, more preferably within about 5 to about 40 seconds, and still more preferably within about 5 to about 30 seconds, for 20 example about 25 seconds, after placement in the oral cavity of a subject.

Solid dosage forms of the invention have a hardness that can depend on size and shape as well as on composition, among other characteristics. Tablet hardness can be measured by any method known in the art, for example by a tablet hardness meter (*e.g.*, Schleuniger). Preferably, compositions of the invention have a hardness 25 of about 1 to about 10 kp, and more preferably of about 1 to about 5 kp.

In a presently preferred embodiment, solid dosage forms of the invention have sufficient hardness for handling and, therefore, can be put into practical use in the same manner as the case of ordinary tablets. The term "sufficient hardness for handling" as used herein means a hardness which can withstand removal from at least 30 a standard type of blister packaging, or such a hardness as will withstand other handling such as packaging, delivery, carrying and the like.

Tablets of the invention preferably have a minimum hardness so as to resist

breakage of the tablet during removal from standard blister packaging by pushing the tablet through a cover sheet. A suitable hardness is about 1 kp or more for a tablet having a diameter of about 8 mm, about 1.5 kp or more for a tablet having a diameter of about 10 mm, and about 2 kp or more when the tablet has a diameter of about

5 12 mm.

In another presently preferred embodiment, tablets of the invention have sufficient hardness such that a plurality of such tablets can be packaged together, for example in a glass or plastic bottle, without individual packaging, yet do not exhibit substantial breakage or sticking and/or melding together during normal shipping and
10 handling. Tablets intended for such packaging preferably have a hardness of about 3 kp or more.

Compositions of the invention can be packaged in any suitable manner known in the art. For example, a multiplicity of fast-melt tablets can be packaged together, for example in a glass or plastic bottle or container. Alternatively, fast-melt tablets of
15 the invention can be individually wrapped, for example in plastic or foil, or packaged in known forms of blister packaging. Blister packaging with improved force distribution properties such as is disclosed in U.S. Patent No. 5,954,204 to Grabowski, incorporated herein by reference, can be especially useful to package fast-melt tablets of the invention.

20 Compositions of the present invention can be taken by a subject by any oral administration means in accordance with the subject's choice or condition. For example, fast-melt tablets of the invention can be taken without water. Upon placement in the oral cavity and especially in the cheek or above the tongue, such a tablet is exposed to saliva and rapidly disintegrates and dissolves therein. The rate of
25 disintegration and/or dissolution increases further when an intraoral pressure, for example a pressure between the palate and tongue or a licking or sucking pressure, is applied to the tablet.

Alternatively, a tablet of the present invention can be taken with the aid of water in an amount sufficient to wet the oral cavity and to assist in disintegration of
30 the tablet. Also, a tablet of the invention can be swallowed together with a small amount of water after complete or partial disintegration in the oral cavity. Compositions of the invention can also be swallowed directly with water.

The process described below is a non-limiting, illustrative method to make celecoxib fast-melt tablets. Importantly, specific settings and parameters of the production process can be readily optimized by one of skill in the art in order to produce tablets with particularly desired characteristics.

- 5 In this illustrative process, celecoxib and low moldability mannitol are de-lumped in a mill or grinder and blended to form a drug powder mixture. Next, this drug powder mixture is wet granulated, preferably by fluid bed granulation, with an aqueous granulation fluid containing a binding agent and, preferably, a wetting agent such as sodium lauryl sulfate in solution. If the granules are not dried during
- 10 granulation, for example as is the case in fluid bed granulation, they are dried after granulation, for example in an oven. The resulting dried granules are then milled to form a milled granulate. The milled granulate is then optionally blended with flavor, sweetener and lubricants in a tumble blender to form a tablet blend. The resulting tablet blend is then compressed on a rotary tablet press to a target tablet weight and
- 15 hardness. The resulting tablets can be subjected to treatment in a humidity-controlled chamber with the effect of increasing tablet hardness.

Fluid bed granulation is the preferred method of wet granulation in processes of the invention, although any known wet granulation method, for example high-shear granulation or pan granulation, can be used.

- 20 Illustratively, in fluid bed granulation, celecoxib, low moldability mannitol, and any other desired excipients are mixed together and sized in a mill or grinder. Next, the resulting drug powder mixture is granulated in a fluid bed by spraying a liquid solution of a binding agent and a wetting agent onto the mixture. The wet granules are then fluid bed dried.

- 25 After fluid bed granulation is complete, the resulting dried granules are then blended with any further desired excipients and then compressed into tablets.

- Alternatively, in high-shear wet granulation, celecoxib, mannitol and any other desired excipients are blended under high shear in a granulator. Next, a liquid solution of a binding agent and a wetting agent are added to the resulting drug powder
- 30 mixture under continuing high shear, thereby forming wet granules.


After high-shear granulation is complete, the resulting granules are then dried, for example, in an oven, microwave or fluid bed. The dried granules are then

transferred to a blender for addition of any other desired excipients to form a tablet blend, which is then compressed.

Compression is the process by which an appropriate volume of a tablet blend of granules produced as described above is compressed between an upper and lower punch to consolidate material into a single solid dosage form such as a tablet. In processes for manufacture of fast-melt tablets of the present invention, any suitable means for compression can be used including, for example, a single punch tablet machine or a high speed rotary tablet press. The tableting pressure is not limited, and an appropriate pressure can be selected depending on the desired hardness and dissolution properties of the resulting tablets.

WHAT IS CLAIMED IS:

1. A process for preparing an oral fast-melt pharmaceutical composition, the process comprising (a) a step of wet granulating a selective cyclooxygenase-2 inhibitory drug together with a binding agent selected from gums, polypeptides,
 5 natural and modified starches, cellulosic materials, alginic acid and salts thereof, polyethylene glycol, polyvinylpyrrolidone, polymethacrylates, silicate salts and bentonites; and (b) a step of blending with the drug a saccharide having low moldability, wherein said steps (a) and (b) occur in any order or simultaneously to result in formation of granules.
- 10 2. The process of Claim 1 wherein said step (b) occurs prior to or simultaneously with said step (a).
3. The process of Claim 1 wherein the selective cyclooxygenase-2 inhibitory drug is a compound having the formula:




- 15 where R^3 is a methyl or amino group, R^4 is hydrogen or a C_{1-4} alkyl or alkoxy group, X is N or CR^5 where R^5 is hydrogen or halogen, and Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl or halomethyl groups; or a prodrug of such a compound.
- 20 4. The process of Claim 3 wherein the five- to six-membered ring is selected from cyclopentenone, furanone, methylpyrazole, isoxazole and pyridine rings substituted at no more than one position.
5. The process of Claim 1 wherein the selective cyclooxygenase-2 inhibitory drug is selected from celecoxib, deracoxib, valdecoxib, rofecoxib, etoricoxib, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one, (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid and 2-(3,4-
- 25

difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3-(2H)-pyridazinone.

6. The process of Claim 1 wherein the selective cyclooxygenase-2 inhibitory drug is celecoxib.
- 5 7. The process of Claim 1 wherein the selective cyclooxygenase-2 inhibitory drug is valdecoxib.
8. The process of Claim 1 wherein the selective cyclooxygenase-2 inhibitory drug is present in an amount of about 0.1% to about 60% by weight of the composition.
- 10 9. The process of Claim 1 wherein the selective cyclooxygenase-2 inhibitory drug is present in a total amount of about 20% to about 60% by weight of the composition.
10. The process of Claim 1 wherein said saccharide having low moldability is selected from lactose, mannitol, glucose, sucrose and xylitol.
- 15 11. The process of Claim 1 wherein said saccharide having low moldability is mannitol of powder grade.
12. The process of Claim 1 wherein said saccharide having low moldability is present in an amount of about 10% to about 90% by weight of the composition.
13. The process of Claim 1, further comprising (c) a step of blending said granules
20 with at least one of a lubricant, a sweetening agent and a flavoring agent to form a tableting blend; and (d) a step of compressing the tableting blend to form oral fast-melt tablets.
14. The process of Claim 16 wherein parameters are set in said compressing step (d) to provide tablets having a hardness of about 1 to about 10 kp.
- 25 15. An oral fast-melt pharmaceutical composition prepared by the process of any of Claims 1 through 14.
16. An oral fast-melt composition comprising a selective cyclooxygenase-2 inhibitory drug dispersed in a matrix comprising a saccharide of low moldability and a binding agent selected from gums, polypeptides, natural and modified

starches, cellulosic materials, alginic acid and salts thereof, polyethylene glycol, polyvinylpyrrolidone, polymethacrylates, silicate salts and bentonites.

17. The composition of Claim 16 wherein the selective cyclooxygenase-2 inhibitory drug is a compound having the formula:



- 5 where R^3 is a methyl or amino group, R^4 is hydrogen or a C_{1-4} alkyl or alkoxy group, X is N or CR^5 where R^5 is hydrogen or halogen, and Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with
- 10 oxo, halo, methyl or halomethyl groups; or a prodrug of such a compound.
18. The composition of Claim 17 wherein the five- to six-membered ring is selected from cyclopentenone, furanone, methylpyrazole, isoxazole and pyridine rings substituted at no more than one position.
- 15 19. The composition of Claim 16 wherein the selective cyclooxygenase-2 inhibitory drug is selected from celecoxib, deracoxib, valdecoxib, rofecoxib, etoricoxib, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one, (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid and 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3-(2H)-pyridazinone.
- 20 20. The composition of Claim 16 wherein the selective cyclooxygenase-2 inhibitory drug is celecoxib.
21. The composition of Claim 16 wherein the selective cyclooxygenase-2 inhibitory drug is valdecoxib.
22. The composition of Claim 16 wherein the selective cyclooxygenase-2 inhibitory drug is present in an amount of about 0.1% to about 60% by weight of the
- 25

composition.

23. The composition of Claim 16 wherein the selective cyclooxygenase-2 inhibitory drug is present in a total amount of about 20% to about 60% by weight of the composition.
- 5 24. The composition of Claim 16 wherein said saccharide having low moldability is selected from lactose, mannitol, glucose, sucrose and xylitol.
25. The composition of Claim 16 wherein said saccharide having low moldability is mannitol of powder grade.
26. The composition of Claim 16 wherein said saccharide having low moldability is present in an amount of about 10% to about 90% by weight of the composition.
- 10 27. The composition of Claim 16 that is a tablet.
28. The tablet of Claim 27 that disintegrates within about 30 to about 300 seconds in a standard *in vitro* disintegration assay.
29. The tablet of Claim 27 that disintegrates within about 5 to about 60 seconds after placement in the oral cavity of a subject.
- 15 30. A method of treating a medical condition or disorder in a mammalian subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising orally administering to the subject a composition of Claim 16.
31. The method of Claim 30 wherein said mammalian subject is a human subject.
- 20 32. The method of Claim 31 that further comprises combination therapy with one or more drugs selected from opioids and other analgesics.
33. The method of Claim 31 that further comprises combination therapy with an opioid compound selected from codeine, meperidine, morphine and derivatives thereof.